Aug 19, 2026, 4:04 PM ETHealthcare
Accuray — Fiscal 2026 Earnings Summary
Financial Performance
- Total net revenue for Q4 2026 was $100.9 million, a 21% decrease year-over-year (YoY) from $127.5 million; for full fiscal 2026, revenue was $401.9 million, a 12% decrease YoY from $458.5 million.
- Product revenue decreased 42% YoY in Q4 to $40.8 million (from $70.7 million) and 27% YoY for the full year to $172.7 million (from $237.6 million).
- Service revenue increased 6% YoY in Q4 to $60.1 million (from $56.8 million) and 4% YoY for the full year to $229.2 million (from $220.9 million).
- Gross profit margin improved to 34.8% in Q4 2026 ($35.1 million) compared to 30.6% in the prior year quarter ($39.0 million); for the full year, gross profit was $111.5 million (27.7% margin) versus $147.0 million (32.1% margin) in the prior year.
- Operating expenses were $29.6 million in Q4 (down 15% YoY) and $137.9 million for the full year (down 1% YoY); full-year expenses included $16.2 million in restructuring charges.
- GAAP net loss was $1.9 million ($0.02 per share) in Q4, compared to net income of $1.1 million ($0.01 per share) in the prior year; for the full year, GAAP net loss was $49.2 million ($0.40 per share) versus a net loss of $1.6 million ($0.02 per share).
- Adjusted EBITDA was $12.9 million in Q4 (up from $9.4 million) and $10.6 million for the full year (down from $28.3 million).
- Gross product orders were $37.7 million in Q4 (down from $84.7 million) and $191.9 million for the full year (down from $288.0 million).
- Book-to-bill ratio was 0.9 in Q4 (down from 1.2) and 1.1 for the full year (down from 1.2).
- Order backlog stood at $312.5 million as of June 30, 2026, approximately 27% lower than the prior year-end.
- Total cash, cash equivalents, and short-term restricted cash were $41.2 million as of June 30, 2026, an increase of $2.7 million from March 31, 2026.
- Long-term debt, net, increased to $146.4 million as of June 30, 2026, from $123.8 million in the prior year; short-term debt, net, decreased to $1.5 million from $12.7 million.
Guidance and Future Outlook
- Management expects continued growth in service revenue and improved service margins driven by pricing optimization and operational efficiencies in fiscal 2027.
- The company anticipates ongoing operating expense discipline and continued benefits from transformation initiatives.
- Strategic partnerships are expected to play an increasingly important role in expanding capabilities while allowing the company to focus on core competencies.
- Due to ongoing uncertainty regarding geopolitical developments, international trade policy, tariff impacts, conditions in China and the Middle East, and broader macroeconomic factors, the company is not providing formal revenue or Adjusted EBITDA guidance for fiscal 2027.
Business Segments and Product Lines
- The transformation plan delivered more than $20 million of cost and margin improvement during fiscal 2026, significantly exceeding the original target of $12 million.
- Service revenue growth reflects continued momentum and a stable foundation for profitable growth in the recurring revenue business.
- The company expanded its strategic partnership ecosystem across imaging, software, engineering, adaptive therapy, research, and customer support to accelerate innovation.
- Strong customer engagement at ESTRO 2026 supported a meaningful increase in qualified commercial opportunities.
Market and Competitive Landscape
- Product demand in certain regions remained impacted by geopolitical developments and tariff uncertainty.
- Strong market interest in Accuray's differentiated technologies was reinforced at ESTRO 2026.
- The company remains focused on its core competencies while leveraging strategic partnerships to expand capabilities.
Risks and Challenges
- Ongoing geopolitical uncertainty, tariff pressures, and market volatility remain key challenges.
- Conditions in China and the Middle East, along with broader macroeconomic factors, create uncertainty for future results.
- Risks include potential disruptions to supply chains, increased logistics costs, and the ability to convert backlog to revenue.
- The company faces risks related to substantial outstanding indebtedness and maintaining compliance with financial covenants.
Management Commentary and Tone
- CEO Steve LaNeve described fiscal 2026 as a "transformational year" where the company strengthened its operational foundation, improved accountability, and enhanced its financial position despite external headwinds.
- CFO Ali Pervaiz noted that while product demand was impacted, the company expanded service revenue, improved efficiency, and executed transformation initiatives ahead of expectations.
- Management stated that Accuray enters fiscal 2027 as a stronger company with greater financial flexibility and a clear focus on sustainable revenue growth, margin expansion, and long-term shareholder value.
Other Key Points
- The company announced a comprehensive financing transaction with TCW Asset Management that strengthens liquidity, reduces leverage, provides covenant relief through December 2027, and enhances financial flexibility.
- The transformation plan successfully delivered over $20 million in cost and margin improvements, surpassing the $12 million target.
- The company is focusing on driving sustainable revenue growth and margin expansion while navigating global macroeconomic conditions.